ZERO Cancer

Contact: Melissa Kadish, Press Secretary
(202) 303-3104
melissa@zerocancer.org
For Immediate Release
May 21, 2012



Government Eliminates Early Detection for Prostate Cancer, Fails American Men

Washington, DC - The United States Preventive Services Task Force has issued its final recommendation for early detection of prostate cancer, effectively eliminating the PSA test and leaving American men without a defense in the fight against prostate cancer.

"We are greatly disappointed by the decision to give the PSA test a "D" rating by United States Preventive Services Task Force,” said Skip Lockwood, CEO of ZERO – The Project to End Prostate Cancer. “We believe that the decision, which eliminates men's access to potentially lifesaving information provided by a PSA test, should not be made by a government panel that doesn’t include a medical oncologist or urologist.”

The USPSTF rated PSA testing “D,” saying there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. This decision contradicts prostate cancer testing recommendations from medical and professional organizations, including the National Comprehensive Cancer Network and American Urological Association.

Since the decision by the USPSTF in 2009 to change prostate cancer testing recommendations for men over the age of 75, no new research has been cited that would call for a drastic change in prostate cancer testing recommendations for all men.

Recent research confirms that the PSA test saves lives. The results of the Göteborg Randomized Population-based Prostate Cancer Screening Trial, released in July 2010, showed a 44 percent decline in prostate cancer deaths as a result of PSA testing. In this Swedish study, partially funded by the National Cancer Institute, an analysis of some 20,000 men was conducted during a 14-year period.

The PSA test and advances in treatment have led to a 40 percent reduction in prostate cancer deaths since the mid-1990s, and 90 percent of all prostate cancers are now discovered before they spread outside the gland. The five-year survival rate is nearly 100 percent when prostate cancer is detected early, while the tumor is still localized and hasn’t spread.

The decision on how best to test and treat for prostate cancer must be made between a man and his doctor and ZERO encourages men to continue to educate themselves and be active participants in their health care. In the absence of an improved test for the disease, ZERO believes that all men, especially those with risk factors, need to consider testing for prostate cancer in order to have the most information possible and make the best health decisions.

For more information on prostate cancer risk, testing and diagnosis, and treatment options, visit www.ZeroCancer.org.


About ZERO — The Project to End Prostate Cancer (zerocancer.org)

At ZERO, we commit ourselves not only to reduce prostate cancer or alleviate the pain from the disease, but also to end it. We see a future where all men who have been diagnosed with prostate cancer will be cured or manage their illness with good quality of life; with the support they need to minimize physical and emotional suffering, and to cope effectively throughout their cancer journey. To accomplish our goal, we provide comprehensive treatment information to patients, education to those at risk and conduct free prostate cancer testing throughout the country. We increase research funds from the federal government to find new treatments and we fund local grants to end the disease.

Powered by ARCOS | Design by Floyd & Partners

ZERO — The End of Prostate Cancer · 515 King St., · Suite 420 · Alexandria, VA 22314 · P: 202-463-9455 · F: 571-257-8559

BBB Accredited Charity Validate TRUSTe privacy certificationZERO does not endorse any course of treatment for men with prostate cancer or other conditions. Treatment decisions should be made by a patient and his health service provider. If you have problems with the site or need more information, please call us at 1.888.245.9455 or e-mail your comments. All names, logos and articles are the copyrights of the respective owners.

© 2011 All Rights Reserved. Contact Us | Privacy Policy